India’s National Pharmaceutical Pricing Authority has raised ceiling prices for two essential platinum-based cancer drugs, cisplatin and carboplatin, by 50% to address shortages linked to rising raw material and manufacturing costs.
This is a direct example of the tension between price control and supply security. Cancer drugs must remain affordable, but if regulated prices fall too far below sustainable production economics, manufacturers may struggle to maintain supply.
The lesson is clear: essential medicine policy cannot focus only on low prices. It must also protect production continuity.
For API and finished-dose producers, platinum price volatility and manufacturing costs are now central supply-chain risks. For hospitals and patients, the policy move may improve availability, but it also shows how fragile essential oncology drug supply can become when input costs move sharply.
